The US Food and Drug Administration has cleared Luminex's xTAG Gastrointestinal Pathogen Panel for use on the firm's benchtop MagPix instrument.

Luminex CEO Patrick Balthrop told BioArray News that the GPP is the "first clinical assay" to be cleared on the compact system, which is gaining a "larger percentage" of the company's installed base of instruments, and that MagPix's clearance will offer the firm access to potential clients who lack the bench space to accommodate its older, larger systems.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.